Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Secure and private NOMA VLC using OFDM with two-level chaotic encryption.

Yang Y, Chen C, Zhang W, Deng X, Du P, Yang H, Zhong WD, Chen L.

Opt Express. 2018 Dec 24;26(26):34031-34042. doi: 10.1364/OE.26.034031.

PMID:
30650833
2.

Modeling the complex exposure history of smoking in predicting bladder cancer: a pooled analysis of 15 case-control studies.

van Osch FHM, Vlaanderen J, Jochems SHJ, Bosetti C, Polesel J, Porru S, Carta A, Golka K, Jiang X, Stern MC, Zhong WD, Kellen E, Pohlabeln H, Tang L, Marshall J, Steineck G, Karagas MR, Johnson KC, Zhang ZF, Taylor JA, La Vecchia C, Bryan RT, van Schooten FJ, Wesselius A, Zeegers MP.

Epidemiology. 2018 Dec 26. doi: 10.1097/EDE.0000000000000964. [Epub ahead of print]

PMID:
30601243
3.

Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8+ tumor-associated lymphocytes and poor prognosis in prostate cancer.

Mo RJ, Han ZD, Liang YK, Ye JH, Wu SL, Lin SX, Zhang YQ, Song SD, Jiang FN, Zhong WD, Wu CL.

Int J Cancer. 2018 Dec 11. doi: 10.1002/ijc.32061. [Epub ahead of print]

PMID:
30537104
4.

Overexpression of TPX2 is associated with progression and prognosis of prostate cancer.

Zou J, Huang RY, Jiang FN, Chen DX, Wang C, Han ZD, Liang YX, Zhong WD.

Oncol Lett. 2018 Sep;16(3):2823-2832. doi: 10.3892/ol.2018.9016. Epub 2018 Jun 25.

5.

Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer.

Liang YK, Han ZD, Lu JM, Liu ZZ, Zhuo YJ, Zhu XJ, Chen JX, Ye JH, Liang YX, He HC, Zhong WD.

J Cell Biochem. 2018 Sep;119(9):7245-7255. doi: 10.1002/jcb.26913. Epub 2018 May 24.

PMID:
29797600
6.

Column generation algorithms for virtual network embedding in flexi-grid optical networks.

Lin R, Luo S, Zhou J, Wang S, Chen B, Zhang X, Cai A, Zhong WD, Zukerman M.

Opt Express. 2018 Apr 16;26(8):10898-10913. doi: 10.1364/OE.26.010898.

PMID:
29716020
7.

Increased intracellular Cl- concentration promotes ongoing inflammation in airway epithelium.

Zhang YL, Chen PX, Guan WJ, Guo HM, Qiu ZE, Xu JW, Luo YL, Lan CF, Xu JB, Hao Y, Tan YX, Ye KN, Lun ZR, Zhao L, Zhu YX, Huang J, Ko WH, Zhong WD, Zhou WL, Zhong NS.

Mucosal Immunol. 2018 Jul;11(4):1149-1157. doi: 10.1038/s41385-018-0013-8. Epub 2018 Mar 15.

PMID:
29545647
8.

GDCRNATools: an R/Bioconductor package for integrative analysis of lncRNA, miRNA and mRNA data in GDC.

Li R, Qu H, Wang S, Wei J, Zhang L, Ma R, Lu J, Zhu J, Zhong WD, Jia Z.

Bioinformatics. 2018 Jul 15;34(14):2515-2517. doi: 10.1093/bioinformatics/bty124.

PMID:
29509844
9.

Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.

Wu S, Ye J, Wang Z, Lin SX, Lu M, Liang Y, Zhu X, Olumi AF, Zhong WD, Wu CL.

Cancer Biol Ther. 2018 Mar 4;19(3):175-180. doi: 10.1080/15384047.2017.1414762. Epub 2018 Jan 17.

10.

SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer.

Yuan D, Wang W, Su J, Zhang Y, Luan B, Rao H, Cheng T, Zhang W, Xiao S, Zhang M, Jiang FN, Sun Z, Jia Z, Zhong WD, Zhu J.

Curr Cancer Drug Targets. 2018;18(9):894-904. doi: 10.2174/1568009618666180102101442.

PMID:
29295692
11.

ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.

Zheng Y, Lin ZY, Xie JJ, Jiang FN, Chen CJ, Li JX, Zhou X, Zhong WD.

Curr Mol Med. 2017;17(3):221-229. doi: 10.2174/1566524017666170807144711.

PMID:
28782483
12.

miR‑30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein.

Huang YQ, Ling XH, Yuan RQ, Chen ZY, Yang SB, Huang HX, Zhong WD, Qiu SP.

Mol Med Rep. 2017 Sep;16(3):2431-2438. doi: 10.3892/mmr.2017.6910. Epub 2017 Jul 4.

13.

Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer.

Chen QB, Liang YK, Zhang YQ, Jiang MY, Han ZD, Liang YX, Wan YP, Yin J, He HC, Zhong WD.

Tumour Biol. 2017 Jun;39(6):1010428317703924. doi: 10.1177/1010428317703924.

PMID:
28651494
14.

Role of GPR30 in estrogen-induced prostate epithelial apoptosis and benign prostatic hyperplasia.

Yang DL, Xu JW, Zhu JG, Zhang YL, Xu JB, Sun Q, Cao XN, Zuo WL, Xu RS, Huang JH, Jiang FN, Zhuo YJ, Xiao BQ, Liu YZ, Yuan DB, Sun ZL, He HC, Lun ZR, Zhong WD, Zhou WL.

Biochem Biophys Res Commun. 2017 Jun 3;487(3):517-524. doi: 10.1016/j.bbrc.2017.04.047. Epub 2017 Apr 12.

PMID:
28412354
15.

MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.

Lin ZY, Chen G, Zhang YQ, He HC, Liang YX, Ye JH, Liang YK, Mo RJ, Lu JM, Zhuo YJ, Zheng Y, Jiang FN, Han ZD, Wu SL, Zhong WD, Wu CL.

Mol Cancer. 2017 Feb 27;16(1):48. doi: 10.1186/s12943-017-0615-x.

16.

Decreased HoxD10 Expression Promotes a Proliferative and Aggressive Phenotype in Prostate Cancer.

Mo RJ, Lu JM, Wan YP, Hua W, Liang YX, Zhuo YJ, Kuang QW, Liu YL, He HC, Zhong WD.

Curr Mol Med. 2017;17(1):70-78. doi: 10.2174/1566524017666170220104920.

PMID:
28231752
17.

High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.

Xie JJ, Zhuo YJ, Zheng Y, Mo RJ, Liu ZZ, Li BW, Cai ZD, Zhu XJ, Liang YX, He HC, Zhong WD.

Int Urol Nephrol. 2017 May;49(5):817-823. doi: 10.1007/s11255-017-1545-7. Epub 2017 Feb 17.

PMID:
28213802
18.

Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.

Wan YP, Xi M, He HC, Wan S, Hua W, Zen ZC, Liu YL, Zhou YL, Mo RJ, Zhuo YJ, Luo HW, Jiang FN, Zhong WD.

Oncol Res Treat. 2017;40(1-2):15-20. doi: 10.1159/000455145. Epub 2017 Jan 25.

19.

Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo.

Xie Q, Wu MY, Zhang DX, Yang YM, Wang BS, Zhang J, Xu J, Zhong WD, Hu JN.

World J Gastroenterol. 2016 Aug 28;22(32):7342-52. doi: 10.3748/wjg.v22.i32.7342.

20.

Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer.

Fu X, Chen G, Cai ZD, Wang C, Liu ZZ, Lin ZY, Wu YD, Liang YX, Han ZD, Liu JC, Zhong WD.

Onco Targets Ther. 2016 Apr 15;9:2211-20. doi: 10.2147/OTT.S101994. eCollection 2016.

Supplemental Content

Loading ...
Support Center